Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome

Dec 16, 2024Cureus

Potential Benefits of GLP-1 Receptor Drugs for Polycystic Ovary Syndrome

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists are associated with significant reductions in body weight, body mass index (BMI), and waist circumference in patients with PCOS.

Treatment with GLP-1 receptor agonists is linked to improvements in insulin sensitivity in women with PCOS.
The review included 11 articles focusing on randomized trials of GLP-1 RAs for managing PCOS symptoms.
Diverse patient presentations and treatment approaches complicate understanding of the exact mechanisms and long-term effects of GLP-1 RAs.
Findings suggest potential therapeutic benefits of GLP-1 agonists in addressing metabolic and reproductive issues related to PCOS.

AI simplified

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting women of reproductive age and is characterized by hormonal imbalances, insulin resistance, and reproductive dysfunctions. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are primarily used in diabetes management to enhance insulin release by stimulating GLP-1 receptors in the pancreas. The search strategy included randomized trials on the management of PCOS symptoms with GLP-1 RAs alone or in combination with other medications; meta-analyses, literature reviews, or case reports were excluded. This scoping review focuses on 11 articles to explore the therapeutic potential of GLP-1 RAs in PCOS patients. The results show significant reductions in body weight, body mass index (BMI), and waist circumference, alongside improvements in insulin sensitivity in PCOS patients treated with GLP-1 agonists. However, the diverse presentation of patients and treatment approaches was a challenge in understanding the exact mechanisms, long-term effects, and safety profiles of GLP-1 RAs in PCOS patients. This study investigates the promising potential of GLP-1 agonists in managing PCOS-related metabolic and reproductive disturbances.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief